KINTOR PHARMA-B Shares Surge Over 9% Again on Cosmetics Venture

Stock News03-16

KINTOR PHARMA-B (09939) rose more than 9% again. At the time of writing, the stock was up 7.27% to HK$4.28, with a turnover of HK$145.832 million.

The surge follows an announcement from KINTOR PHARMA that its wholly-owned subsidiary has entered into a strategic cooperation agreement with Funuo Pharmaceutical. The two parties will jointly develop functional cosmetics for skin whitening and spot removal, utilizing KINTOR PHARMA's innovative raw material KT-939 as the core ingredient. This collaboration aims to provide a new auxiliary solution for improving skin pigmentation and treating melasma.

The company plans to use the cash flow generated from the KT-939 functional cosmetics raw material business to fund the development and commercialization of its core products, KX-826 and GT20029, as well as other pipeline products.

Notably, KINTOR PHARMA recently stated on an investor platform that the Phase III clinical top-line data for its self-developed topical androgen receptor (AR) antagonist, KX-826 1.0% tincture for the treatment of male androgenetic alopecia (AGA), is scheduled for official disclosure in mid-to-late March 2026. Backed by solid clinical data, KX-826 has successfully obtained an International Nomenclature of Cosmetic Ingredients (INCI) name, qualifying it as a compliant cosmetic raw material.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1191230208?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 10:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191230208","market":"us","top_or_hot":-1,"title":"KINTOR PHARMA-B Shares Surge Over 9% Again on Cosmetics Venture","media":"Stock News","content":"<p>KINTOR PHARMA-B (09939) rose more than 9% again. At the time of writing, the stock was up 7.27% to HK$4.28, with a turnover of HK$145.832 million.</p>\n<p>The surge follows an announcement from KINTOR PHARMA that its wholly-owned subsidiary has entered into a strategic cooperation agreement with Funuo Pharmaceutical. The two parties will jointly develop functional cosmetics for skin whitening and spot removal, utilizing KINTOR PHARMA's innovative raw material KT-939 as the core ingredient. This collaboration aims to provide a new auxiliary solution for improving skin pigmentation and treating melasma.</p>\n<p>The company plans to use the cash flow generated from the KT-939 functional cosmetics raw material business to fund the development and commercialization of its core products, KX-826 and GT20029, as well as other pipeline products.</p>\n<p>Notably, KINTOR PHARMA recently stated on an investor platform that the Phase III clinical top-line data for its self-developed topical androgen receptor (AR) antagonist, KX-826 1.0% tincture for the treatment of male androgenetic alopecia (AGA), is scheduled for official disclosure in mid-to-late March 2026. Backed by solid clinical data, KX-826 has successfully obtained an International Nomenclature of Cosmetic Ingredients (INCI) name, qualifying it as a compliant cosmetic raw material.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>KINTOR PHARMA-B Shares Surge Over 9% Again on Cosmetics Venture</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKINTOR PHARMA-B Shares Surge Over 9% Again on Cosmetics Venture\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-16 10:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>KINTOR PHARMA-B (09939) rose more than 9% again. At the time of writing, the stock was up 7.27% to HK$4.28, with a turnover of HK$145.832 million.</p>\n<p>The surge follows an announcement from KINTOR PHARMA that its wholly-owned subsidiary has entered into a strategic cooperation agreement with Funuo Pharmaceutical. The two parties will jointly develop functional cosmetics for skin whitening and spot removal, utilizing KINTOR PHARMA's innovative raw material KT-939 as the core ingredient. This collaboration aims to provide a new auxiliary solution for improving skin pigmentation and treating melasma.</p>\n<p>The company plans to use the cash flow generated from the KT-939 functional cosmetics raw material business to fund the development and commercialization of its core products, KX-826 and GT20029, as well as other pipeline products.</p>\n<p>Notably, KINTOR PHARMA recently stated on an investor platform that the Phase III clinical top-line data for its self-developed topical androgen receptor (AR) antagonist, KX-826 1.0% tincture for the treatment of male androgenetic alopecia (AGA), is scheduled for official disclosure in mid-to-late March 2026. Backed by solid clinical data, KX-826 has successfully obtained an International Nomenclature of Cosmetic Ingredients (INCI) name, qualifying it as a compliant cosmetic raw material.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1191230208","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191230208","pubTimestamp":1773629353,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"KINTOR PHARMA-B (09939) rose more than 9% again. At the time of writing, the stock was up 7.27% to HK$4.28, with a turnover of HK$145.832 million. The surge follows an announcement from KINTOR PHARMA...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1161":"生物科技","BK1515":"抗疫概念","BK4585":"ETF&股票定投概念","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","BK1574":"生物医药B类股","BK4115":"综合电信业务","KT":"韩国电信","LU0541502299.USD":"ALLSPRING  EMERGING MARKETS EQUITY \"I\" (USD) ACC","09939":"开拓药业-B","LU0541501648.USD":"ALLSPRING  EMERGING MARKETS EQUITY \"A\" (USD) ACC","VXUS":"国际股票ETF-Vanguard","BK4588":"碎股"},"translate_title":"开拓药业-B股因化妆品风险投资再次飙升逾9%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"VXUS":1,"09939":1,"KT":1},"content_text":"KINTOR PHARMA-B (09939) rose more than 9% again. At the time of writing, the stock was up 7.27% to HK$4.28, with a turnover of HK$145.832 million.\nThe surge follows an announcement from KINTOR PHARMA that its wholly-owned subsidiary has entered into a strategic cooperation agreement with Funuo Pharmaceutical. The two parties will jointly develop functional cosmetics for skin whitening and spot removal, utilizing KINTOR PHARMA's innovative raw material KT-939 as the core ingredient. This collaboration aims to provide a new auxiliary solution for improving skin pigmentation and treating melasma.\nThe company plans to use the cash flow generated from the KT-939 functional cosmetics raw material business to fund the development and commercialization of its core products, KX-826 and GT20029, as well as other pipeline products.\nNotably, KINTOR PHARMA recently stated on an investor platform that the Phase III clinical top-line data for its self-developed topical androgen receptor (AR) antagonist, KX-826 1.0% tincture for the treatment of male androgenetic alopecia (AGA), is scheduled for official disclosure in mid-to-late March 2026. Backed by solid clinical data, KX-826 has successfully obtained an International Nomenclature of Cosmetic Ingredients (INCI) name, qualifying it as a compliant cosmetic raw material.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1191230208","isCrawlerRequest":true}